Board of Directors

Andy Hull

Chair of the Board of Directors

Andy Hull has over 30 years of experience in various commercial and business development roles with leading pharmaceutical and biotech companies. He spent 16 years at Takeda Pharmaceuticals in various leadership roles. As Senior Vice President of Marketing, he was responsible for Takeda’s United States product portfolio of over $3 billion.

He also served as Senior Vice President of Business Development and Strategic Product Planning where he led the US BD team in partnerships, licensing, and acquisitions, and as Head of Global Alliances where he was responsible for maximizing the success of Takeda’s growing number of commercial and R&D partnerships. Prior to Takeda, Andy was Vice President of Specialty Therapeutics Marketing at Immunex prior to its acquisition by Amgen. In addition, he spent 13 years at Abbott in various sales and marketing roles.

Andy received a bachelor’s degree in Biology from Kenyon College in 1985. He recently served as a member and chair of the Board of Directors of the Illinois Biotechnology Innovation Organization, a recent Board member of Zucara Therapeutics, and a recent member of the Kenyon College Board of Trustees.

Learn More

Bryan Baldasare

Director

Mr. Baldasare is a well-rounded biotech executive with wealth of experience in finance and accounting, financial planning and analysis, treasury management, commercial operations and mergers and acquisitions.

Mr. Baldasare spent over 20 years at Meridian Bioscience, most recently as Chief Financial Officer where during his tenure, grew its revenues by over 500%, developed and launched dozens of new products, expanded into a diversified global business with 15 sites in 10 countries. Mr. Baldasare is currently the CFO at Hilltop Companies, a leading supplier to the construction industry. Prior to Meridian, Mr. Baldasare spent over 10 years in public accounting at Arthur Andersen LLP.

Mr. Baldasare has a Bachelor’s degree in Business Administration from the University of Cincinnati.

Learn More

Nicole Lemerond, CFA

Director

Nicole Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance.

She has significant experience executing complex transactions, managing diligence processes, raising capital and structuring balance sheets. Throughout her career, Ms. Lemerond has worked with public and private company management teams and boards to increase stakeholder value. She established and led healthcare groups at leading investment firms and has also worked at several large financial institutions, including Lehman Brothers and The Carlyle Group.

Ms. Lemerond holds a Bachelor of Science degree from Cornell University and is a CFA charterholder.

Learn More

Eric A. Adams, MIBS

Chief Executive Officer & President

Mr. Adams is a seasoned biopharmaceutical executive with more than 30 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance.

Mr. Adams has been our President and Chief Executive Officer, and a Director, since 2016. He previously served as CEO at enGene Inc. Prior to enGene, he held senior roles in global market development with QLT Inc., Advanced Tissue Sciences Inc., Abbott Laboratories, and Fresenius AG (Germany).

He is a dual citizen of Canada and the United States and holds a Masters of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana.

Learn More

Novel Cannabinoid Analogs

Our patentable cannabinoid analogs can be slightly modified to target specific pharmacological properties.

Learn More

Management

Learn More

Scientific Advisory Board

Learn More